[Skip to Navigation]
November 1994

Detection of Vascular Endothelial Growth Factor Messenger RNA and Vascular Endothelial Growth Factor-like Activity in Proliferative Diabetic Retinopathy

Author Affiliations

From the Laboratory of Molecular Biology, CNRS (Drs Malecaze, Simorre-Pinatel, Chollet, and Plouet), the Laboratory of Ophthalmology, (Drs Malecaze, Simorre-Pinatel, Mathis, and Chollet), University of Toulouse (France), the Laboratory of Endocrinology, National Institute of Health and Medical Research (INSERM) (Ms Clamens and Dr Bayard), Toulouse, France; and the Department of Ophthalmology, Hotel Dieu, Paris, France (Dr Favard).; Dr Malecaze is now with the Department of Ophthalmology, Hopital Purpan, Toulouse, France.

Arch Ophthalmol. 1994;112(11):1476-1482. doi:10.1001/archopht.1994.01090230090028

Objective:  To study the involvement of eight angiogenic growth factors that have been identified so far in the literature, especially vascular endothelial growth factor, in proliferative diabetic retinopathy.

Methods:  Samples of neovascular membranes were obtained from diabetic patients; these samples, excised at vitrectomy, were used to study the expression of messenger RNA of the angiogenic factors by using the method of the reverse transcription-polymerase chain reaction. Vitreous aspirates that were taken from diabetic and control patients were used to quantify vascular endothelial growth factor-like activity with a competitive radioreceptor assay.

Results:  Of the eight angiogenic factors studied, vascular endothelial growth factor was the only one that was always expressed in the samples of neovascular membranes. Furthermore, vascular endothelial growth factor receptor-binding activity was greater in vitreous aspirates that were obtained from diabetic patients than in samples that were taken from control patients (P<.01).

Conclusion:  Vascular endothelial growth factor seems to be an appropriate candidate for mediating retinal diabetic neovascularization.

Add or change institution